ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

VXRT Vaxart Inc

0.7401
-0.0089 (-1.19%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Vaxart Inc NASDAQ:VXRT NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.0089 -1.19% 0.7401 0.73 1.00 0.7494 0.69 0.749 2,158,370 05:00:09

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing In Biota Pharmaceuticals, Inc. (BOTA) To ...

10/05/2014 2:42am

PR Newswire (US)


Vaxart (NASDAQ:VXRT)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Vaxart Charts.

NEW YORK, May 9, 2014 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Biota Pharmaceuticals, Inc. ("Biota" or the "Company") (NasdaqGS: BOTA).

Faruqi & Faruqi, LLP.

On April 29, 2014 Biota revealed alarming news about the Company. The 8-K stated, in relevant part, that Biota "has been notified by the U.S. Department of Health and Human Services (HHS) office of the Assistant Secretary for Preparedness and Response (ASPR) and Biomedical Advanced Research and Development Authority (BARDA) that pending a decision regarding the outcome of a recently completed In Process Review (IPR) of the Company's contract for the development of laninamivir octanoate, which the Company is developing for the treatment of influenza A and B infections in the United States through a contract with BARDA, ASPR/BARDA, has issued a Stop-Work Order notifying the Company to discontinue work on a number of activities under its contract."

The April 29 disclosure caused Biota shares to plummet by $1.93, or roughly 34 percent, from the previous day's closing price of $5.57.

Request more information now by clicking here:  www.faruqilaw.com/BOTA. There is no cost or obligation to you.

Take Action

If you invested in Biota stock or options and would like to discuss your legal rights, visit www.faruqilaw.com/BOTA.  You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding Biota's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising.  The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).  Prior results do not guarantee or predict a similar outcome with respect to any future matter.  We welcome the opportunity to discuss your particular case.  All communications will be treated in a confidential manner.

FARUQI & FARUQI, LLP
369 Lexington Avenue, 10th Floor
New York, NY 10017
Attn:  Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330

Logo - http://photos.prnewswire.com/prnh/20120119/MM38856LOGO

SOURCE Faruqi & Faruqi, LLP

Copyright 2014 PR Newswire

1 Year Vaxart Chart

1 Year Vaxart Chart

1 Month Vaxart Chart

1 Month Vaxart Chart

Your Recent History

Delayed Upgrade Clock